Journal: Translational Psychiatry

Article Title: Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode

doi: 10.1038/tp.2012.112

Figure Lengend Snippet: Gene ontology analysis of dysregulated genes (FDR⩽5%)

Article Snippet: CELF2 , A_23_P115645 , Hs00990166_m1 , 1.54 , 1.05 , 1.08 , 1.06 , 1.48 , 1.14 , 1.01 , 1.09 , 0.985 , No.

Techniques: Membrane, Binding Assay

Journal: Translational Psychiatry

Article Title: Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode

doi: 10.1038/tp.2012.112

Figure Lengend Snippet: qPCR validation of candidate gene expression

Article Snippet: CELF2 , A_23_P115645 , Hs00990166_m1 , 1.54 , 1.05 , 1.08 , 1.06 , 1.48 , 1.14 , 1.01 , 1.09 , 0.985 , No.

Techniques: Biomarker Discovery, Microarray

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: CELF2 Expression Is Downregulated in Ovarian Cancer and Predicts Poor Prognosis (A) Method used to screen differentially expressed RBPs in ovarian cancer through a comprehensive analysis of three datasets. (B) The expression of 28 key RBPs in our microarray data from 10 ovarian cancer tissues and 8 normal ovarian tissues is presented in a heatmap. (C) Expression of the CELF2 mRNA in 50 ovarian cancer specimens and 50 normal ovarian surface epithelial specimens analyzed using qRT-PCR (p = 0.0005). (D) Western blot showing CELF2 levels in six ovarian cancer tissues and six normal ovarian tissues. (E) Representative images and proportions of negative, weakly positive, moderately positive, and strongly positive CELF2 immunohistochemical (IHC) staining in normal ovarian tissues (left panel) and ovarian cancer tissues (right panel) (scale bars, 40 μm). (F) Representative images of negative, weakly positive, moderately positive, and strongly positive IHC staining for CELF2 in ovarian cancer tissues (scale bars, 200 μm and 40 μm). (G) A Kaplan-Meier analysis was performed to assess the associations between CELF2 expression and the OS (p = 0.0096) and PFS (p = 0.0014) of patients with ovarian cancer. Data are presented as mean ± SEM.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Expressing, Microarray, Quantitative RT-PCR, Western Blot, Immunohistochemical staining, Immunohistochemistry

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: Effects of CELF2 on the Proliferation and Migration of Ovarian Cancer Cells In Vitro (A) Western blot and qRT-PCR analyses of CELF2 expression in 11 ovarian cancer cell lines. (B) qRT-PCR and western blot analyses of CELF2 levels following CELF2 overexpression and knockdown. (C–E) CCK-8 (C), colony-formation (D), and Transwell assays (E) (scale bars, 40 μm) were performed to assess the changes in the proliferation and migration induced by CELF2. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Migration, In Vitro, Western Blot, Quantitative RT-PCR, Expressing, Over Expression, Knockdown, CCK-8 Assay

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: Overexpression of CELF2 Inhibited Proliferation and Metastasis In Vivo (A) Xenografts were established in BALB/c nude mice by subcutaneously injecting CELF2-overexpressing SK-OV-3 cells (CELF2) or vector-expressing cells (NC) and xenograft tumor growth curves of the CELF2 and NC groups (right panel). (B) Final tumor weights of xenograft tumors at sacrifice. (C) Representative images of H&E staining and IHC staining for CELF2 and the proliferation marker Ki-67 in fixed and embedded xenograft tumors (scale bars, 100 μm). (D) Representative images of luciferase signals (left panel) and quantification of photon flux in abdominal cavity metastatic luciferase foci (right panel) after the intraperitoneal injection of CELF2-overexpressing SK-OV-3 cells (CELF2) or vector-expressing cells (NC) in BALB/c nude mice. (E) Representative images of abdominal cavity metastases derived from two groups after sacrifice (left panel) and quantification of the number of metastatic nodules of tumors in the abdominal cavities (right panel). Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Over Expression, In Vivo, Plasmid Preparation, Expressing, Staining, Immunohistochemistry, Marker, Luciferase, Injection, Derivative Assay

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: CELF2 Stabilized the FAM198B Transcript (A) Venn diagram illustrating the overlap of 23 mRNA targets of CELF2 identified using the RIP-seq and RNA-seq analysis (left panel); eight transcripts were also dysregulated in the GEPIA database (right panel). (B) qRT-PCR analysis of eight transcripts obtained from RIP with anti-CELF2 and IgG control antibodies in A2780 cells. (C) Levels of the FAM198B mRNA and protein in CELF2-overexpressing CAOV-3 and SK-OV-3 cells and CELF2 knockdown A2780 and OVCAR-8 cells were analyzed using qRT-PCR and western blotting, respectively. (D) After treatment with 5 μg/mL Act D, total RNA was extracted at 0, 4, 8, and 12 h. The half-lives of FAM198B mRNA in CELF2-overexpressing CAOV-3 and SK-OV-3 cells and CELF2-knockdown A2780 and OVCAR-8 cells were measured. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001; NS, not significant.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: RNA Sequencing, Quantitative RT-PCR, Control, Knockdown, Western Blot

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: CELF2 Binding to the 3′ UTR of FAM198B mRNA (A) Schematic of various regions in the 3′ UTR of the FAM198B mRNA. (B and C) The relative luciferase activity of the reporter containing each region of the FAM198B 3′ UTR (B) or a mutated sequence of CELF2 target binding sites (C) was measured as a ratio of luciferase activity induced by CELF2 overexpression or knockdown to the luciferase activity of a control vector with no additional 3′ UTR sequence. Data are presented as mean ± SEM. ∗∗∗p < 0.001.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Binding Assay, Luciferase, Activity Assay, Sequencing, Over Expression, Knockdown, Control, Plasmid Preparation

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: FAM198B Is a Tumor Suppressor in Ovarian Cancer (A) Relative expression of the FAM198B mRNA in a cohort of 50 ovarian cancer specimens and 50 normal ovarian surface epithelial specimens determined using qRT-PCR. (B) Correlation of the expression of the CELF2 and FAM198B mRNAs in ovarian tumors (n = 50) from our cohort. (C) Association between FAM198B expression and the OS (p = 0.014) of patients with ovarian cancer in an online database. (D) FAM198B was knocked down by two siRNAs. (E–G) CCK-8 (E), colony-formation (F), and Transwell assays (G) (scale bars, 40 μm) were performed to assess the changes in the proliferation and migration following FAM198B modulation. Data are presented as mean ± SEM. ∗∗p < 0.01 and ∗∗∗p < 0.001.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Expressing, Quantitative RT-PCR, CCK-8 Assay, Migration

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: CELF2 Inhibited Ovarian Cancer Cell Progression in a FAM198B-Mediated Manner (A and B) CELF2-overexpressing CAOV-3 and SK-OV-3 cells were transfected with siRNAs targeting FAM198B. (C–E) CCK-8 (C), colony-formation (D), and Transwell assays (E) (scale bars, 40 μm) were performed to assess changes in proliferation and migration. (F) KEGG analysis showing the main signaling pathways associated with these differentially expressed genes targeted by CELF2. (G) Western blot analysis of ERK and p-ERK levels after the overexpression or knockdown of CELF2. (H) Western blot analysis of ERK and p-ERK levels after the knockdown of FAM198B in CELF2-overexpressing CAOV-3 and SK-OV-3 cells. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Transfection, CCK-8 Assay, Migration, Protein-Protein interactions, Western Blot, Over Expression, Knockdown

Journal: Molecular Therapy. Nucleic Acids

Article Title: The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

doi: 10.1016/j.omtn.2020.10.011

Figure Lengend Snippet: Curcumin Enhanced the Efficacy of Cisplatin in Ovarian Cancer by Upregulating CELF2 (A) The IC 50 value of cisplatin was determined in CELF2-overexpressing CAOV-3 and SK-OV-3 cells and CELF2 knockdown A2780 and OVCAR-8 cells. (B) CAOV-3 and A2780 cells were treated with increasing curcumin concentrations and then subjected to western blotting. (C) The IC 50 value of cisplatin was measured after the addition of curcumin to CAOV-3 and A2780 cells. (D) A colony-formation assay was performed to assess the proliferation of CAOV-3 and A2780 cells after the addition of cisplatin and curcumin alone and in combination. Data are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.

Article Snippet: The CELF2 overexpression plasmid was constructed by cloning the full-length CELF2 cDNA into the pCDH-CMV-MCS-EF1-puro vector (System Biosciences, CA, USA).

Techniques: Knockdown, Western Blot, Colony Assay